ADL-5747 was a novel opioid analgesic drug, however its development was halted because it did not pass

phase II trials The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases ...

Mechanism of action

ADL-5747 is an opioid analgesic, it works by activating opioid receptors. However, unlike ''"classical"''

opioids Opioids are a class of Drug, drugs that derive from, or mimic, natural substances found in the Papaver somniferum, opium poppy plant. Opioids work on opioid receptors in the brain and other organs to produce a variety of morphine-like effects, ...

such as

morphine Morphine, formerly also called morphia, is an opiate that is found naturally in opium, a dark brown resin produced by drying the latex of opium poppies (''Papaver somniferum''). It is mainly used as an analgesic (pain medication). There are ...

, it is selective for the delta receptor. In tests done on mice, ADL-5747 was able to reduce pain in an efficient way. This compound does not seem to cause receptor internalization.

References

{{Opioid receptor modulators Piperidines Chromanes Spiro compounds 2-Hydroxyphenyl compounds Benzamides Delta-opioid receptor agonists Abandoned drugs